Stock comparison
Haemonetics
HUTCHMED (China) Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
HCM
HUTCHMED (China) Limited
Market cap
$2.09B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | HCM | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 15F | HAE |
| Benjamin Graham | 85A | 35D | HAE |
| Philip Fisher | 60C | 18F | HAE |
| Peter Lynch | 54C | 31F | HAE |
| Joel Greenblatt | 31F | 35D | HCM |
| Charlie Munger | 54D | 14F | HAE |
| Terry Smith | 55D | 15F | HAE |
Side-by-side metrics
| Metric | HAE | HCM |
|---|---|---|
| Market cap | $2.98B | $2.09B |
| P/E (TTM) | 24.8x | 4.8x |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -0.69% |
| Gross margin | 55.74% | 18.62% |
| Net margin | 7.29% | 104.77% |
| Revenue CAGR 5y | 7.65% | 11.48% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- ROIC (TTM)8.37%vs -0.69%+108%
- Gross margin55.74%vs 18.62%+67%
- Market cap$2.98Bvs $2.09B+30%
HCM leads on
- EV/EBIT-vs 14.1x+135%
- Debt / Equity0.1xvs 1.5x+95%
- Net margin104.77%vs 7.29%+93%
- P/E (TTM)4.8xvs 24.8x+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.